Metabolism of the epoxy resin component 2,2-bis[4](2,3]epoxypropoxy)phenyl]propane, the diglycidyl ether of bisphenol A (DGEBPA) in the mouse. Part I. A comparison of the fate of a single dermal application and of a single oral dose of 14C-DGEBPA.
1. 14C-DGEBPA dermally applied to mice was only slowly eliminated in the feces (20% dose) and urine (3%), as a mixture of metabolites, over three days. Most of the applied radioactivity (66% dose) was extracted from the application area and its covering foil. 2. When 14C-DGEBPA was given orally to mice it was rapidly excreted; 80% of the administered 14C was eliminated in the feces and 11% in the urine 0-3 days after a single oral dose. 3. The urinary faecal metabolite profiles derived from dermal application and oral dosing were essentially similar.
D000284:Administration, Oral; D000287:Administration, Topical; D000818:Animals; D001559:Benzhydryl Compounds; D004852:Epoxy Compounds / Q000378:metabolism*; D004988:Ethers, Cyclic / Q000378:metabolism*; D005243:Feces / Q000032:analysis; D008297:Male; D051379:Mice; D010647:Phenyl Ethers / Q000378:metabolism; D012867:Skin; D014018:Tissue Distribution; D000098826:Bisphenol A Compounds
D001559:Benzhydryl Compounds; D004852:Epoxy Compounds; D004988:Ethers, Cyclic; D010647:Phenyl Ethers; C019273:bisphenol A diglycidyl ether; D000098826:Bisphenol A Compounds